Founded in 1996 under Sinopharm Group, it is a well-known contraceptive brand, specializing in the R&D/production and sales of various new pharmaceutical preparations/biopharmaceuticals/chemical raw materials and traditional Chinese medicine preparations

Shanghai Modern Pharmaceutical Co., Ltd. (hereinafter referred to as "Sinopharm Modern") is a high-tech pharmaceutical enterprise founded in 1996 and listed on the Shanghai Stock Exchange on June 16, 2004 (stock code: 600420, stock abbreviation: Modern Pharmaceutical). In April 2010, he joined China National Pharmaceutical Group Corporation and became one of the enterprises directly under China National Pharmaceutical Industry Research Institute.

Sinopharm Modern's main business is the production and sales of pharmaceuticals, and its product line covers chemical raw materials, new pharmaceutical preparations, biopharmaceuticals and Chinese patent medicines. At present, there are 3 production plants and 7 wholly-owned or holding subsidiaries. In the past six years, the compound growth rate of economic benefits has maintained a rate of more than 17%, and the market share of key products has remained at the forefront.

Many of Sinopharm Modern products have been included in the second prize of the National Science and Technology Progress Award, the National Key Science and Technology Research Project, the National Torch Program Project, the Shanghai High-tech Achievement Transformation Project, the Shanghai Torch Program Project, and have won the National Key New Product Award, the first prize of the Shanghai Science and Technology Progress Award, the Shanghai Science and Technology Achievement Award, the Shanghai Excellent New Product Award, the Shanghai Famous Brand Product and the Shanghai Pharmaceutical Industry Famous Product for many times.

Modern pharmaceutical parent production plant

Pudong plant: production of controlled-release preparations (1 variety), oral solid preparations (more than 30 specifications), high-end, new APIs (more than 10 varieties); The key varieties are nifedipine controlled-release tablets, enalapril maleate tablets, lipoic acid, azithromycin, and etoposide; APIs, solid oral preparations and ointments have all passed the new GMP certification.

Jiading plant: production of sustained-release capsules, sustained-release suspensions (5 specifications), oral solid preparations (4 specifications); The key varieties were dextromethorphan sustained-release suspension and cephalosporin series; All of them have passed the new GMP certification.

Nanxiang Factory: Production of external preparations (surgery, gynecology), traditional Chinese medicine preparations (more than 30 specifications) and traditional Chinese medicine extracts; The key varieties are terconazole, indomethacin, family planning drugs and other suppositories, centella asiatica series, ironing; All of them have passed the new GMP certification.